Welcome to the UPF Digital Repository

Current controversies in the stepping up and stepping down of inhaled therapies for COPD at the patient level

Show simple item record

dc.contributor.author Lopez-Campos, Jose Luis
dc.contributor.author Carrasco Hernández, Laura
dc.contributor.author Muñoz, Xavier
dc.contributor.author Bustamante, Víctor
dc.contributor.author Barreiro Portela, Esther
dc.date.accessioned 2019-07-25T07:43:17Z
dc.date.available 2019-07-25T07:43:17Z
dc.date.issued 2018
dc.identifier.citation Lopez-Campos JL, Carrasco Hernández L, Muñoz X, Bustamante V, Barreiro E. Current controversies in the stepping up and stepping down of inhaled therapies for COPD at the patient level. Respirology. 2018 Jun 20. DOI: 10.1111/resp.13341
dc.identifier.issn 1323-7799
dc.identifier.uri http://hdl.handle.net/10230/42174
dc.description [AHEAD] Data de publicació electrónica: 20-06-2018
dc.description.abstract The implementation of potential new step-up or step-down treatment recommendations in response to current guidelines is one of the main challenges currently faced in actual daily practice settings. In the present narrative review, we aim to discuss the relevance of these step-up and step-down proposals at the patient level in daily clinical practice. In particular, we aim to review the challenges associated with inhaled maintenance therapy for chronic obstructive pulmonary disease (COPD) in four clinical scenarios. First, we discuss the step up from single to double bronchodilation, including current controversies regarding the addition of a second bronchodilator versus initial treatment with two bronchodilators. Second, we discuss the step up from double bronchodilation to triple therapy while challenging current indications for inhaled steroid therapy and discussing triple therapy designs. Third, we discuss the step down from triple therapy to double bronchodilation while evaluating the effect of this downshift in risk categories on the patient according to the new classifications. Finally, we discuss the step down from double to single bronchodilation, with a special focus on safety. We believe this review will help to highlight the most relevant discussion points regarding the treatment of COPD in a manner that will stimulate and guide related clinical research.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Wiley
dc.rights This is the peer reviewed version of the following article: Lopez-Campos JL, Carrasco Hernández L, Muñoz X, Bustamante V, Barreiro E. Current controversies in the stepping up and stepping down of inhaled therapies for COPD at the patient level. Respirology. 2018 Jun 20, which has been published in final form at http://dx.doi.org/10.1111/resp.13341. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
dc.title Current controversies in the stepping up and stepping down of inhaled therapies for COPD at the patient level
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1111/resp.13341
dc.subject.keyword Chronic obstructive pulmonary disease
dc.subject.keyword Inhaled therapy
dc.subject.keyword Pharmacological treatment
dc.subject.keyword Step-down
dc.subject.keyword Step-up
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/acceptedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

Compliant to Partaking